JMP Securities raised the firm’s price target on Acadia Pharmaceuticals to $42 from $39 and keeps an Outperform rating on the shares following the Q3 results. The sales performance of NUPLAZID and DAYBUE remains strong as broad clinical development continues to move forward, the analyst tells investors in a research note.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on ACAD: